BioSpace News Archive

Hemoconcentrators, also referred to as hemofilters or ultrafiltration devices, which contain a semipermeable membrane that allows passage of water and electrolytes out of the blood.

Cornea can be defined as a transparent dome-shaped covering on the eye, which covers the pupil, the iris and the anterior chamber of the eye.

Macrolides is a class of antibacterial drugs that contain a large macrocyclic lactone ring substituted with certain unusual sugars.

The demand within the global punctuate keratitis market is set to grow at a starry pace in the years to follow.

Shahinian cannula is an ophthalmic instrument used for irrigation and probing of the lacrimal duct.

Cellular Biomedicine Group Inc. announced that the Food and Drug Administration granted C-CAR039, a novel autologous bi-specific CAR-T therapy targeting both CD19 and CD20 antigens, both Regenerative Medicine Advanced Therapy Designation and Fast Track Designation for the treatment of patients with relapsed or refractory diffuse large B cell lymphoma.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent for the company’s subcutaneous formulation of levosimendan.

Antares Pharma, Inc., a specialty pharmaceutical company, announced the appointment of Claude E. Richardson as Senior Vice President of Human Resources.

Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its third fiscal quarter 2021, ended December 31, 2021.

Athenex, Inc. announced that it has entered into a definitive agreement for ImmunityBio, Inc. to assume its leasehold interest in a manufacturing facility in Dunkirk, New York, and certain related assets for approximately $38 million, subject to adjustment at closing.